D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and efficacy
darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination
(FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir
disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as
determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir